Skip to content
Peptigraph home

VIP Benefits: Claims vs What Studies Show

Benefits people claim for VIP, set against what published studies measured, and where no study exists.

Medical review pendingVasoactive intestinal peptideUpdated
Strongest evidence
Human RCT
Human / animal studies
10 / 0
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
compounded or research

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

VIP claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Immune systemHuman RCT evidence, 4 of 44 / 0Time to discharge; Day-90 ordinal outcome; Mortality to day 90Evidence for immune system
Heart healthHuman RCT evidence, 4 of 43 / 0Airway function and cardiovascular effect; Pulmonary vasodilation; Blood pressure and vasodilationEvidence for heart health
Erectile dysfunctionHuman observational evidence, 3 of 41 / 0Efficacy (resumption of penetrative sexual activity); Intracavernosal VIP plus phentolamine for EDNone
InflammationHuman observational evidence, 3 of 42 / 0Symptom reversal after multi-part treatment; TNF-alpha production and regulatory T cellsEvidence for inflammation
EnergyHuman observational evidence, 3 of 41 / 0Symptom reversal after multi-part treatmentEvidence for energy
Gut healthHuman observational evidence, 3 of 41 / 0Symptom reversal after multi-part treatmentEvidence for gut health

Strongest study per claim: Immune system, Medical principles and practice 2025, PMID 39870064; Heart health, Thorax 1986, PMID 3787552; Erectile dysfunction, The journal of sexual medicine 2025, PMID 40192471.

What the studies measured

VIP outcomes in published studies
OutcomeResultStudy typeSource
Time to dischargeAverage time to discharge was 7.8 days on inhaled aviptadil versus 10 days on placebo (p = 0.049).Human RCTn = 80Medical principles and practice 2025, PMID 39870064
Day-90 ordinal outcomeAviptadil did not significantly improve the day-90 outcome category.Human RCTn = 461The Lancet. Respiratory medicine 2023, PMID 37348524
Mortality to day 90Day-90 mortality was 38% on aviptadil and 36% on placebo with no significant difference.Human RCTn = 461The Lancet. Respiratory medicine 2023, PMID 37348524
Primary endpoint (alive and free of respiratory failure at day 60)The primary endpoint was not met (OR 1.6, 95% CI 0.86-3.11).Human RCTn = 196Critical care medicine 2022, PMID 36044317
60-day survival (secondary)A secondary survival analysis showed two-fold odds of survival (OR 2.0, p = 0.035).Human RCTn = 196Critical care medicine 2022, PMID 36044317
Airway function and cardiovascular effectAt 6 pmol/kg/min infused VIP lowered systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min, with no change in airway conductance.Human controlled trialThorax 1986, PMID 3787552
Efficacy (resumption of penetrative sexual activity)About 59% found the aviptadil plus phentolamine injection effective, in a retrospective non-controlled series; the formulation is not VIP alone.Human observationaln = 308The journal of sexual medicine 2025, PMID 40192471
OxygenationMean oxygen saturation rose from 87.86% to 93.43% after 3 days of infusion, in a small uncontrolled series.Human observationaln = 6Indian journal of critical care medicine 2024, PMID 38510776
Symptom reversal after multi-part treatmentSymptoms resolved after removal of biotoxin exposure plus VIP replacement, dental extractions and a relaxation program; the effect of VIP alone cannot be separated.Human case reportn = 1The American journal of case reports 2016, PMID 27165859
TNF-alpha production and regulatory T cellsNebulized VIP was well tolerated and reduced TNF-alpha production by lung lavage cells in sarcoidosis.Human uncontrolled trialn = 20American journal of respiratory and critical care medicine 2010, PMID 20442436
Pulmonary vasodilationA single inhaled aviptadil dose had a modest, short-lived vasodilating effect with no side effects reported.Human uncontrolled trialn = 20The European respiratory journal 2008, PMID 18978135
Blood pressure and vasodilationVIP infusion caused sustained vasodilatation and lowered total peripheral resistance by 30% and mean arterial pressure by 12%.Human uncontrolled trialn = 6The American journal of cardiology 1987, PMID 3687785
Survival odds vs placeboThe two RCTs together showed no survival benefit (OR 1.01, p = 0.93).Meta-analysisn = 665Indian journal of critical care medicine 2025, PMID 41368449
Intracavernosal VIP plus phentolamine for EDThe review reports effectiveness in at least 80% of men with ED in clinical studies; this is a company-product review, not primary data.ReviewBJU international 2008, PMID 18485029
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “aviptadil[tiab]”: 30 results. PubMed search on 2 Oct 2026 for “aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt])”: 6 results. PubMed search on 2 Oct 2026 for “(aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab])”: 1,509 results. PubMed search on 2 Oct 2026 for “(aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 70 results.

Claimed: help for lung inflammation and COVID

In the large US trial of intravenous aviptadil in COVID-19 respiratory failure, the odds of a better day-90 outcome category were 1.11 versus placebo, a non-significant result (p=0.54).[2]

A smaller trial missed its primary endpoint but reported a secondary survival signal, with odds of improved survival at 60 days of 2.0 (p = 0.035).[3]

An 80-patient trial of inhaled aviptadil reported average time to discharge of 7.8 days versus 10 days with placebo (p = 0.049).[1]

A meta-analysis of the two randomized trials found a survival odds ratio of 1.01 versus placebo, which indicates no significant benefit.[11]

Claimed: better sexual function

In a retrospective review of men with refractory erectile dysfunction, 182 men (59%) found an aviptadil plus phentolamine injection into the penis effective; this was not a controlled trial and not subcutaneous or nasal VIP.[5]

Claimed: calming inflammation and gut problems

In sarcoidosis patients, inhaled VIP was safe, well tolerated and reduced the production of tumor necrosis factor-alpha by lung lavage cells, in an uncontrolled study.[8]

For the gut claim, the only record is a single case report in which symptoms resolved after removing mould exposure, VIP replacement, dental extractions and a relaxation programme together, so VIP's own effect cannot be separated.[7]

Heart effects seen in people

In healthy volunteers, infused VIP at 6 pmol/kg/min lowered mean systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min; that is a vasodilator effect, not a benefit.[4]

No study for energy

The evidence file lists no human study of VIP or aviptadil for energy or fatigue other than the single multi-part case report, so an energy benefit is unsupported by trial data here.

Calculated from evidence file web/src/data/evidence/vip.json; energy trials 0; case reports 1. Formula: energy trials = 0; case reports = 1 and it combined four interventions

Common questions

Is VIP proven to work?

The strongest study we summarise for VIP is human rct evidence, among 12 studies. A trial result is not an approval; see the legal status.

What does VIP peptide do?

As a naturally occurring signalling peptide it dilates blood vessels, and an infusion study found it lowered blood pressure in healthy people.[10]

More on VIP

Sources

  1. 1Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025PMID 39870064Accessed 2 Oct 2026
  2. 2Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
  3. 3The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
  4. 4Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
  5. 5Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.The journal of sexual medicine · 2025PMID 40192471Accessed 2 Oct 2026
  6. 6Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024PMID 38510776Accessed 2 Oct 2026
  7. 7Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures.The American journal of case reports · 2016PMID 27165859Accessed 2 Oct 2026
  8. 8Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.American journal of respiratory and critical care medicine · 2010PMID 20442436Accessed 2 Oct 2026
  9. 9Inhalation of vasoactive intestinal peptide in pulmonary hypertension.The European respiratory journal · 2008PMID 18978135Accessed 2 Oct 2026
  10. 10Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
  11. 11Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025PMID 41368449Accessed 2 Oct 2026
  12. 12Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.BJU international · 2008PMID 18485029Accessed 2 Oct 2026
  13. 13PubMed search: aviptadil[tiab] (30 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (1509 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (70 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: "vasoactive intestinal peptide"[tiab] AND (CIRS[tiab] OR "inflammatory response syndrome"[tiab] OR mycotoxin*[tiab] OR "water-damaged"[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: "vasoactive intestinal peptide"[tiab] AND ("clinical trial"[pt] OR randomized[tiab]) AND (inhal*[tiab] OR intranasal[tiab] OR sarcoid*[tiab] OR "pulmonary hypertension"[tiab] OR ARDS[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: aviptadil[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  20. 20PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (humans[mh]) (94 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.